March 29, 2002 |
Cardiac Science Inc. said it filed a lawsuit accusing rival Zoll Medical Corp. of stealing its patented ideas for heart defibrillators. Zoll said Tuesday it received Food and Drug Administration approval for an automated external defibrillator that can be used by people such as lifeguards, flight attendants and security guards. Cardiac Science claims Zoll's new defibrillator uses technology covered by two Cardiac Science patents.
September 26, 2001 |
Defibrillator maker Cardiac Science Inc. said this week that shareholders have approved the Irvine company's acquisition of Survivalink Corp., a Minneapolis maker of external defibrillators, for $71 million in cash and stock. Shareholders also approved an increase in the number of authorized shares to a maximum of 100 million from 40 million, Cardiac said.
June 15, 2001 |
Cardiac Science Inc. said Thursday that continued reviews by federal regulators have delayed for a third time its plans to acquire a Swedish maker of patient monitors and defibrillators. The struggling Irvine maker of defibrillators said in a news release that the pending $20-million stock swap to purchase Artema Medical AB was delayed "to satisfy U.S. regulatory requirements." Cardiac, whose accountants raised doubts in February about its ability to survive, has been trying to raise money.
April 10, 2001 |
More defibrillator developments: Cardiac Science Inc. of Irvine has won Canadian regulatory approval for the Powerheart, a defibrillator worn by hospital patients to monitor heart rates and deliver jolts during cardiac arrest. With a population of about 30 million, Canada is a good market for Cardiac, Chief Executive Raymond W. Cohen said. The Powerheart is now available in 32 countries, including the Czech Republic and Australia.
April 10, 2001
Cardiac Science Inc., an Irvine maker of defibrillator devices and monitoring software, reported a fourth-quarter net loss of nearly $7.4 million, or 30 cents a share, up from $2.9 million, or 25 cents per share, a year earlier. Sales rose to about $1.5 million from $103,000. For the year, Cardiac lost $32.9 million, or $1.82 per share, compared with $7.7 million, or 85 cents per share, in 1999. The most recent loss included noncash charges of $16.
March 14, 2001
Cardiac Science Inc. said its planned acquisition of Artema Medical, a Swedish maker of patient monitors and defibrillators, should close in the first week in June, about a month later than previously estimated. Cardiac, an Irvine manufacturer of external defibrillators, said the stock acquisition "is a relatively lengthy and complex process" because of regulatory requirements in Sweden as well as in the U.S.